Serotonin

Serotonin is a systemic stress mediator whose elevation Ray Peat consistently linked to low metabolic energy, degeneration, and the aging process, directly contradicting its cultural branding as the “happy hormone.” 3 Peat argued that the popular narrative was manufactured, tracing its origins to a misinterpretation of LSD’s mechanism; researchers found that LSD reduced serotonin, and when high doses caused psychosis, the opposite—that serotonin must promote sanity—became the entrenched dogma. 2 He viewed serotonin not as a simple neurotransmitter acting on discrete receptors, but as a substance involved in field-like formative processes that shape how the organism adapts to stress, with its effects depending on the entire energetic context of the cell. 5

The synthesis and action of serotonin are intimately tied to stress physiology and energy failure. Peat detailed that the primary driver of brain serotonin synthesis is increased free tryptophan in the blood, which occurs when stress-induced lipolysis releases free fatty acids that displace tryptophan from albumin; this is exacerbated by hypoglycemia, not sugar consumption. 1 At the cellular level, the rate-limiting enzyme tryptophan hydroxylase (TPH) is activated by excitation, increased intracellular calcium, and a reductive cellular state—a condition of low oxygen and glucose utilization that Peat identified as a common factor in shock and degeneration, challenging the exclusive focus on oxidative stress. 1 Once synthesized, serotonin activates the pituitary-adrenal axis to increase cortisol and prolactin, hormones that further suppress mitochondrial respiration and promote tissue catabolism. 6 Estrogen amplifies this system by increasing serotonin synthesis and inhibiting its degradation, while carbon dioxide and thyroid function act as the primary physiological antagonists, inhibiting serotonin release. 2

Approximately 90-95% of the body’s serotonin is produced in the intestine, where it functions as a major mediator of inflammation and a link between gut irritation and systemic disease. 2 Peat explained that mechanical irritation of the intestine is sufficient to release serotonin, which then increases the permeability of the gut and blood vessels, promoting the absorption of endotoxin and other harmful materials. 7 This gut-derived serotonin is a central driver of pathology; Georgi Dinkov has cited evidence that inhibiting gut serotonin synthesis with a TPH-1 inhibitor has the same protective metabolic effects as sterilizing the gut, identifying serotonin as the direct pathological agent downstream of bacterial overgrowth. 10 Dinkov further notes that serotonin is a potent profibrotic mediator, with pharmaceutical companies quietly developing serotonin antagonists for fibrosis while marketing SSRIs that increase serotonin availability. 2

The clinical consequences of elevated serotonin span from mood disorders to structural degeneration. Peat and Roddy have highlighted that every anti-serotonin drug has demonstrated antidepressant effects in animal models, and that the serotonin antagonist mianserin is approved for treatment-resistant depression, undermining the low-serotonin hypothesis of depression. 2 Roddy characterizes serotonin as a signal for withdrawal and torpor, promoting a state of discomfort and depression rather than alert pleasure. 2 Beyond the brain, serotonin’s profibrotic effects directly damage tissues; Dinkov describes how SSRIs accelerate degenerative mitral regurgitation by blocking the serotonin transporter, leaving excess serotonin to stimulate collagen overproduction in heart valves, a mechanism confirmed in both human observational studies and animal models. 11 Peat identified serotonin as a major factor in osteoporosis and other aging-related degenerative changes, cementing its role as a central mediator of the structural decline that accompanies low metabolic energy. 3